Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 27% Improvement Relative Risk Mortality (b) 50% levels Mortality (c) 40% levels c19early.org/d Subramanian et al. Vitamin D for COVID-19 Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Prospective study of 467 patients in the United Kingdom Lower mortality with vitamin D (not stat. sig., p=0.12) Subramanian et al., The American J. Clinical Nut.., doi:10.1093/ajcn/nqac027 Favors vitamin D Favors control
Vitamin D, D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients
Subramanian et al., The American Journal of Clinical Nutrition, doi:10.1093/ajcn/nqac027
Subramanian et al., Vitamin D, D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients, The American Journal of Clinical Nutrition, doi:10.1093/ajcn/nqac027
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 427 hospitalized COVID-19 patients in the United Kingdom, showing lower mortality with vitamin D supplementation (p=0.12), and higher mortality with both low and high vitamin D levels compared to a reference range of 50-74 nmol/L.
risk of death, 27.3% lower, RR 0.73, p = 0.12, treatment 31 of 131 (23.7%), control 80 of 336 (23.8%), adjusted per study, odds ratio converted to relative risk, prescribed supplement use, multivariable.
risk of death, 49.7% lower, RR 0.50, p = 0.02, high D levels 16 of 115 (13.9%), low D levels 33 of 118 (28.0%), NNT 7.1, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, 50-74 nmol/L vs. <25nmol/L, multivariable, outcome based on serum levels.
risk of death, 39.7% lower, RR 0.60, p = 0.07, high D levels 16 of 115 (13.9%), low D levels 38 of 157 (24.2%), NNT 9.7, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, 50-74 nmol/L vs. 25-49nmol/L, multivariable, outcome based on serum levels.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Subramanian et al., 31 Jan 2022, prospective, United Kingdom, peer-reviewed, 16 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Vitamin D, D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. Short title: Vitamin D and COVID-19 mortality PT Martin Hewison5, Rene F Chun6, Andrea Jorgensen7, Paul Richardson1, Darshan Nitchingham1, RI Joseph Aslan1, Maya Shah1, Coonoor R Chandrasekar8, Amanda Wood9, Mike Beadsworth10, Department of Gastroenterology, Liverpool University Hospital Foundation NHS Trust, Liverpool, N U 1 SC Munir Pirmohamed11 Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University M 2 A UK 3 IT ED of Liverpool Department of Clinical Chemistry, Liverpool University Hospital Foundation NHS Trust, Liverpool, UK Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, ED 4 N Liverpool, UK Institute of Metabolism and Systems Research, University of Birmingham 6 Department of Orthopaedic Surgery, University of California, Los Angeles 7 Department of Health Data Science, University of Liverpool, Liverpool, UK 8 Department of Orthopaedic Surgery, Liverpool University Hospital Foundation NHS Trust, IN A L U 5 Department of Clinical Pharmacology, Liverpool University Hospital Foundation NHS Trust, O RI 9 G Liverpool, UK Liverpool, UK © Crown copyright 2022. This article contains public sector information licensed under the Open Government Licence v3.0 (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/). Sreedhar Subramanian1, 2 ¶, Jonathan M Rhodes2, , Joseph M Taylor3, Anna M Milan3, Steven Lane4, 10 Tropical and Infectious Diseases Unit, Liverpool University Hospital Foundation NHS Trust, Liverpool, UK 11 Department of Molecular and Clinical Pharmacology, University of Liverpool ¶ Corresponding author: Consultant Gastroenterologist and Honorary Senior Lecturer PT Department of Gastroenterology RI Liverpool University Hospital Foundation NHS Trust and University of Liverpool SC Prescot Street Liverpool L7 8XP, UK N U Email: sreedhar.subramanian@liverpoolft.nhs.uk A Acknowledgements: None M Registration: The study protocol was approved by the London-Surrey Research Ethics Committee IT ED (20/HRA/2282). Funding Source: This research was funded by an internal departmental grant from Liverpool ED University Hospitals NHS Foundation Trust. The funders had no input into study design or final Guarantor of the article A L U Dr Sreedhar Subramanian N analysis. IN Author contributions: SS, JR, MP, JT and AM were involved in study design and initial drafting G of the manuscript. SL was involved in data analysis. All authors revised and approved the final O RI version of the manuscript. Sreedhar Subramanian, MD, FRCP Conflict of interest: JMR with the University of Liverpool and Provexis UK, holds a patent for use of a soluble fibre preparation as maintenance therapy for Crohn’s disease plus a patent for its use in antibiotic-associated diarrhoea. Patent also held with the University of Liverpool and others in relation to use of modified heparins in cancer therapy. SS has received speaker fees from MSD, Actavis, Abbvie, Dr Falk pharmaceuticals, Janssen, Takeda, Boehringer-Ingelheim, Shire and Abbvie, Dr Falk..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit